Press Releases


  • Preparation displays good tolerability and safety
  • Study goals attained with fewer patients than planned
  • Follow-up studies in planning
The biotechnology company MOLOGEN AG today announces that the primary study...


The biotechnology company MOLOGEN AG has expanded its scientific advisory board. With Stefan M. Manth, MD, PhD, MBA, the advisory committee has been joined by a top manager from the pharmaceutical industry with extensive experience in the strategic...


  •  Economic development running according to plan
For MOLOGEN AG, the third quarter of 2011 was characterized by the two running clinical studies. First very positive results from the phase I/II clinical study of renal cancer...


  • Compound shows very good tolerability and safety
  • Efficacy data much better than expected
Today, MOLOGEN AG published the first results from the phase I/II clinical trial with the cell-based renal cancer therapy MGN1601....


  • Phase II/III of colorectal cancer study with MGN1703 have also begun in Russia
  • Clinical study II/III for the treatment of lung cancer under preparation
In the first half of 2011, MOLOGEN AG concentrated above all on its...


  • Application for pivotal phase II/III clinical trial in preparation
  • Expansion of the product pipeline with further blockbuster candidate
  • Lung cancer is one of the most prevalent forms of cancer worldwide


  • Revenues of 10 million euro from capital increase
  • European patent for renal cancer medicine MGN1601
  • Further clinical trial being planned with MGN1703 in new cancer indication
MOLOGEN AG has made a successful start...


Displaying results 1 bis 7 von 14

Page 1

Page 2



3 Questions to Dr. Söhngen

Dr. Mariola Söhngen CEO MOLOGEN AG

Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

[email protected]